share_log

Genmab A/S (OTCMKTS:GNMSF) Sees Large Drop in Short Interest

Genmab A/S (OTCMKTS:GNMSF) Sees Large Drop in Short Interest

Genmab A/S(OTCMKTS：GNMSF)湖上空头股数大跌
kopsource ·  2022/09/28 21:43

Genmab A/S (OTCMKTS:GNMSF – Get Rating) was the target of a large decline in short interest during the month of September. As of September 15th, there was short interest totalling 10,900 shares, a decline of 71.7% from the August 31st total of 38,500 shares. Based on an average daily volume of 1,400 shares, the short-interest ratio is currently 7.8 days.

Genmab A/S(场外交易平台：GNMSF-GET评级)是空头股数9月份大幅下跌的目标。截至9月15日，空头股数共有10,900股，比8月31日的38,500股下降了71.7%。以日均成交量1,400股计算，目前短息比率为7.8天。

Genmab A/S Price Performance

Genmab A/S性价比

Shares of Genmab A/S stock traded up $10.50 during trading on Wednesday, hitting $324.00. 822 shares of the stock were exchanged, compared to its average volume of 1,136. The stock has a market cap of $21.18 billion, a price-to-earnings ratio of 34.99 and a beta of 0.77. The firm's 50-day moving average price is $352.46 and its 200 day moving average price is $336.97. Genmab A/S has a 12-month low of $260.25 and a 12-month high of $479.99.

在周三的交易中，Genmab A/S的股价上涨了10.5美元，达到324.00美元。该股共成交822股，而其平均成交量为1,136股。该股市值为21.8亿美元，市盈率为34.99倍，贝塔系数为0.77。该公司的50日移动均线价格为352.46美元，200日移动均线价格为336.97美元。Genmab A/S的12个月低点为260.25美元，12个月高位为479.99美元。

Get
到达
Genmab A/S
Genmab A/S
alerts:
警报：

Genmab A/S (OTCMKTS:GNMSF – Get Rating) last released its quarterly earnings data on Wednesday, August 10th. The company reported $4.10 earnings per share (EPS) for the quarter. The business had revenue of $452.87 million during the quarter. Genmab A/S had a net margin of 38.42% and a return on equity of 17.12%.

Genmab A/S(OTCMKTS：GNMSF-GET Rating)最近一次发布季度收益数据是在8月10日星期三。该公司公布该季度每股收益(EPS)为4.10美元。该业务本季度的收入为4.5287亿美元。Genmab A/S的净利润率为38.42%，股本回报率为17.12%。

About Genmab A/S

关于Genmab A/S

(Get Rating)
(获取评级)

Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; ofatumurnab, a human monoclonal antibody to treat chronic lymphocytic leukemia (CLL) and multiple sclerosis; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC.

Genmab A/S主要在丹麦开发用于治疗癌症和其他疾病的抗体疗法。该公司销售用于治疗多发性骨髓瘤(MM)患者的人类单抗DARZALEX；用于治疗甲状腺眼病的teprotomumab；用于治疗慢性淋巴细胞白血病(CLL)和多发性硬化症的人类单抗Ofatumurnab；以及用于晚期或转移性胃癌、食道癌和非小细胞肺癌的Amivantamab。

Featured Articles

专题文章

  • Get a free copy of the StockNews.com research report on Genmab A/S (GNMSF)
  • Can United Natural Foods Fight Both Inflation and the Fed?
  • Mullen Automotive Is Ready To Get In Gear
  • Cracker Barrel: A Tasty Treat Or Bad Apple?
  • Defensive Stocks For A Volatile Market
  • Will UPS Be Next to Deliver a Warning?
  • 免费获取StockNews.com关于Genmab A/S(GNMSF)的研究报告
  • 联合天然食品能同时对抗通胀和美联储吗？
  • 马伦汽车已做好准备投入使用
  • 饼干桶：可口的款待还是坏苹果？
  • 防御性股票应对动荡的市场
  • UPS会成为下一个发出警告的公司吗？

Receive News & Ratings for Genmab A/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Genmab A/S and related companies with MarketBeat.com's FREE daily email newsletter.

接受Genmab A/S日报的新闻和评级-在下面输入您的电子邮件地址，通过MarketBeat.com的免费每日电子邮件时事通讯接收对Genmab A/S和相关公司的最新新闻和分析师评级的每日简要摘要。

声明：本内容仅用作提供资讯及教育之目的，不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    抢沙发